Taeun Kang: Beyond Traditional ‘Blood Thinners’ – Cardiovascular and Thrombosis Therapeutics
Taeun Kang, Founder and Chief Growth Officer of Manhattan Signal, shared a post on LinkedIn:
“Pause and Note – Cardiovascular and Thrombosis Therapeutics
As shared previously, I have been spending more time independently researching cardiovascular therapeutics, thrombosis prevention, and emerging RNA-based medicines simply out of personal interest and curiosity around where the biotech and pharmaceutical industries may be heading.
Based on my research, below is a high-level market snapshot that I thought some people in biotech/pharma – and especially families impacted by cardiovascular conditions – may also find interesting.
It appears that the landscape is evolving beyond traditional ‘blood thinners’ into much more targeted next-generation cardiovascular approaches.
Current leaders still include major anticoagulants and antiplatelet therapies such as:
- Eliquis
- Xarelto
- Pradaxa
- Plavix
- Brilinta
At the same time, increasing attention appears to be shifting toward:
- Lp(a)-lowering therapies
- FXIa inhibitors
- RNA-based cardiovascular medicines
- Precision thrombosis prevention
Particularly interesting is the growing focus around Lipoprotein(a) [Lp(a)], which continues drawing attention in cardiovascular risk and thrombosis research.
Some major programs currently being watched across the industry include:
- Pelacarsen – Novartis
- Olpasiran – Amgen
- Zerlasiran – Silence Therapeutics
- Lepodisiran – Eli Lilly
I also found it fascinating how multiple modalities are emerging simultaneously, including:
- siRNA
- Antisense oligonucleotides (ASO)
- FXIa inhibition pathways
The intersection of RNA therapeutics, cardiovascular medicine, and preventative care may become one of the more important biotech themes of the next decade.
Question: How can we speed up these new emerging therapies?
To be continued”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers